Nicox reaches FDA review with NCX 470 after two Phase 3 trials beat glaucoma pressure baseline
FDA has accepted Kowa’s NDA for NCX 470 and set an April 30, 2027 PDUFA date after two Phase 3 trials established noninferiority to latanoprost in lowering intraocular pressure.